ERBB2 and gastric cancer: Trastuzumab and TrasGEX are known as beneficial anti-HER2 mAbs for targeting breast or stomach cancers, H2Mab-19 could be also a useful tool for investigating ADCC, CDC, antitumor activities for oral cancers.